Endogenous Cushing’s Syndrome (CS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Endogenous Cushing’s Syndrome (CS) Market Outlook

Thelansis’s “Endogenous Cushing’s Syndrome (CS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Endogenous Cushing’s Syndrome (CS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Endogenous Cushing’s Syndrome (CS) Overview

Endogenous Cushing’s syndrome (CS) is an uncommon endocrine disorder characterized by an overproduction of cortisol stemming from either ACTH-dependent conditions, typically an ACTH-producing pituitary adenoma (known as Cushing’s disease), or ACTH-independent causes, most commonly a benign adrenal adenoma. While the primary effects of endogenous Cushing’s syndrome are evident in its phenotypic changes and metabolic consequences, it also significantly impacts other endocrine axes. Inappropriate cortisol secretion can disrupt the activity of the hypothalamus-pituitary-thyroid axis, resulting in clinical and biochemical features indicative of “central hypothyroidism.” Medical treatment for Cushing’s disease is primarily utilized as a secondary option following unsuccessful surgery or recurrence. It involves various pituitary-directed medications, adrenal steroidogenesis inhibitors, and a glucocorticoid receptor blocker, some of which have received approval from the US Food and Drug Administration (FDA). Notably, recent consensus guidelines from the Pituitary Society endorse osilodrostat, an oral 11β-hydroxylase inhibitor, as an effective FDA-approved medical therapy for Cushing’s disease. Despite achieving remission, patients often contend with several persistent comorbidities that can significantly impact their quality of life. Hence, prompt and accurate diagnosis, followed by timely intervention, is imperative for mitigating the chronic complications associated with excessive glucocorticoid levels and enhancing patient well-being.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Endogenous Cushing’s Syndrome (CS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034